Osteoporosis and fractures in HIV/hepatitis C virus coinfection: A systematic review and meta-analysis

AIDS

Volumn 28, Issue 14, 2014, Pages 2119-2131

  Dong, Huan V ^a   Cortés, Yamnia I ^b   Shiau, Stephanie ^c,d   Yin, Michael T ^e  

^a Clinical Nutrition   (United States)

^b School of Nursing   (United States)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^d Department of Epidemiology ^*  (United States)

^e NewYork Presbyterian Hospital   (United States)

Author keywords

Bone; Coinfection; Fracture; Hepatitis C virus; HIV; Osteoporosis

Indexed keywords

ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BONE DENSITY; COCHRANE LIBRARY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MEDLINE; MIXED INFECTION; OSTEOPOROSIS; PREDICTIVE VALUE; PREVALENCE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK FACTOR; SCOPUS; SMOKING; SUBSTANCE USE; SYSTEMATIC REVIEW; ALCOHOLISM; CHEMICALLY INDUCED; DIRECTIVE COUNSELING; DRUG DEPENDENCE; FRACTURES, BONE; HIV INFECTIONS; IMMUNOLOGY; META ANALYSIS; METABOLISM; ODDS RATIO; PATHOPHYSIOLOGY;

CALCIUM; VITAMIN D;

ALCOHOLISM; BONE DENSITY; CALCIUM; COINFECTION; DIRECTIVE COUNSELING; FRACTURES, BONE; HEPATITIS C; HIV INFECTIONS; HUMANS; ODDS RATIO; OSTEOPOROSIS; PREVALENCE; RISK FACTORS; SMOKING; SUBSTANCE-RELATED DISORDERS; VITAMIN D;

EID: 84906935528     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000363     Document Type: Article

References (53)

1. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51: 729-733.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342.
3. Loria I, Albanese C, Giusto M, Galtieri PA, Giannelli V, Lucidi C, et al. Bone disorders in patients with chronic liver disease awaiting liver transplantation. Transplant Proc 2010; 42: 1191-1193.
4. Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transplant 2003; 9: 1166-1173.
5. Lin JC, Hsieh TY, Wu CC, Chen PJ, Chueh TH, Chang WK, et al. Association between chronic hepatitis C virus infection and bone mineral density. Calcif Tissue Int 2012; 91: 423-429.
6. Lo Re V 3rd, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, et al. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology 2012; 56: 1688-1698.
7. Gallego-Rojo FJ, Gonzalez-Calvin JL, Muñoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998; 28: 695-699.
8. Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, Casado-Caballero F, Ruiz-Escolano E, Olivares EG. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 2004; 89: 4325-4330.
9. Leslie WD, Bernstein CN, Leboff MS, American Gastroenterological Association Clinical Practice. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125: 941-966.
10. Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology 2001; 33: 301-307.
11. Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transplant 2003; 9: 1166-1173.
12. Sandler NG, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141: 1220-12301230 e1-3.
13. Pacifici R. T cells: critical bone regulators in health and disease. Bone 2010; 47: 461-471.
14. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51: 937-946.
15. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-Analytic review. AIDS 2006; 20: 2165-2174.
16. Shiau S, Broun EC, Arpadi SM, Yin MT. Incident fractures in HIV-infected individuals: a systematic review and meta-Analysis. AIDS 2013; 27: 1949-1957.
17. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992-1002.
18. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-837.
19. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999; 29: 150-154.
20. Lo Re V 3rd, Guaraldi G, Leonard MB, Localio AR, Lin J, Orlando G, et al. Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. AIDS 2009; 23: 2191-2198.
21. Young B, Dao CN, Buchacz K, Baker R, Brooks JT, Investigators HIVOS. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52: 1061-1068.
22. Diamantopoulos AP, et al. Short-And long-Term mortality in males and females with fragility hip fracture in Norway. A population-based study. Clin Interv Aging 2013; 8: 817-823.
23. Haentjens P, et al. Meta-Analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152: 380-390.
24. Abrahamsen B, et al. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 2009; 20: 1633-1650.
25. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2013.
26. Womack JA, Goulet JL, Gibert C, Brandt CA, Skanderson M, Gulanski B, et al. Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis 2013; 56: 1498-1504.
27. Maalouf N, Zhang S, Drechsler H, Brown G, Tebas P, Bedimo R. Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients. J Bone Miner Res 2013; 28: 2577-2583.
28. Anastos K, Lu D, Shi O, Mulligan K, Tien PC, Freeman R, et al. The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antiviral Ther 2007; 12: 1049-1058.
29. Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010; 24: 2827-2833.
30. Lawson-Ayayi S, Cazanave C, Kpozehouen A, Barthe N, Mehsen N, Hessamfar M, et al. Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort. J Acquir Immune Defic Syndr 2013; 62: 430-435.
31. Sharma A, Cohen HW, Freeman R, Santoro N, Schoenbaum EE. Prospective evaluation of bone mineral density among middle-Aged HIV-infected and uninfected women: association between methadone use and bone loss. Maturitas 2011; 70: 295-301.
32. Tsai MS, Hung CC, Liu WC, Chen KL, Chen MY, Hsieh SM, et al. Reduced bone mineral density among HIV-infected patients in Taiwan: prevalence and associated factors. J Microbiol Immunol Infect 2014; 47: 109-115.
33. Yin M, McMahon DJ, Ferris DC, Zhang CA, Shu A, Staron R, et al. Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2010; 95: 620-629.
34. Yin MT, Shi Q, Hoover DR, Anastos K, Sharma A, Young M, et al. Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS 2010; 24: 2679-2686.
35. Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009; 23: 1021-1024.
36. El-Maouche D, Mehta SH, Sutcliffe C, Higgins Y, Torbenson MS, Moore RD, et al. Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection. J Hepatol 2011; 55: 770-776.
37. Maalouf NM, Zhang S, Drechsler H, Brown GR, Tebas P, Bedimo R. Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients. J Bone Miner Res 2013; 28: 2577-2583.
38. Sharma A, Flom PL, Weedon J, Klein RS. Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS 2010; 24: 2337-2345.
39. Lawson-Ayayi S, Cazanave C, Kpozehouen A, Barthe N, Mehsen N, Hessamfar M, et al. Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort. J Acquir Immune Defic Syndr 2013; 62: 430-435.
40. Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish populationbased cohort study. AIDS 2012; 26: 285-293.
41. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129.
42. Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabo EV, Melzi S, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 2006; 38: 893-897.
43. Orsini LG, Pinheiro MM, Castro CH, Silva AE, Szejnfeld VL. Bone mineral density measurements, bone markers and serum vitamin D concentrations in men with chronic noncirrhotic untreated hepatitis C. PLoS One 2013; 8: e81652.
44. Hofmann WP, Kronenberger B, Bojunga J, Stamm B, Herrmann E, Bucker A, et al. Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon alpha and ribavirin therapy. J Viral Hepat 2008; 15: 790-796.
45. Redondo-Cerezo E, Casado-Caballero F, Martin-Rodriguez JL, Hernandez-Quero J, Escobar-Jimenez F, Gonzalez-Calvin JL. Bone mineral density and bone turnover in noncirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-Alfa and ribavirin. Osteoporos Int 2014pii: S0168-8278(14)00151-2. doi: 10.1016/j.jhep.2014.03.007. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/ pubmed/24650694.
46. Eg Hansen AB, Haukali Omland L, Krarup H, Obel N. Fracture risk in hepatitis C virus infected persons: results from the DANVIR cohort study. J Hepatol 2014pii: S0168-8278(14)00151-2. doi: 10.1016/j.jhep.2014.03.007. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24650694.
47. Pignata S, Daniele B, Galati MG, Esposito G, Vallone P, Fiore F, et al. Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1997; 9: 283-286.
48. Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995; 108: 276-283.
49. Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, et al. Reduced bone mineral density and altered bone turnover markers in patients with noncirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11: 1843-1847.
50. Pelazas-Gonzalez R, Gonzalez-Reimers E, Aleman-Valls MR, Santolaria-Fernandez F, Lopez-Prieto J, Gonzalez-Diaz A, et al. Bone alterations in hepatitis C virus infected patients. Eur J Intern Med 2013; 24: 92-96.
51. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Sezaki H, et al. Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus. J Med Virol 2010; 82: 390-395.
52. Solis-Herruzo JA, Castellano G, Fernandez I, Munoz R, Hawkins F. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 2000; 33: 812-817.
53. Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-Alpha. J Biol Chem 2002; 277: 2695-2701.